China Oncology Based In-vivo Cro Market Size & Outlook
China oncology based in-vivo cro market, 2018-2030 (US$M)
Related Markets
China oncology based in-vivo cro market highlights
- The China oncology based in-vivo cro market generated a revenue of USD 31.4 million in 2023 and is expected to reach USD 63.2 million by 2030.
- The China market is expected to grow at a CAGR of 10.5% from 2024 to 2030.
- In terms of segment, solid tumor was the largest revenue generating indication in 2023.
- Solid Tumor is the most lucrative indication segment registering the fastest growth during the forecast period.
Oncology based in-vivo cro market data book summary
| Market revenue in 2023 | USD 31.4 million |
| Market revenue in 2030 | USD 63.2 million |
| Growth rate | 10.5% (CAGR from 2023 to 2030) |
| Largest segment | Solid tumor |
| Fastest growing segment | Solid Tumor |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Blood Cancer, Solid Tumor |
| Key market players worldwide | Charles River Laboratories International Inc, Icon PLC, Thermo Fisher Scientific Inc, Eurofins Scientific SE, Labcorp Holdings Inc, Wuxi AppTec Co Ltd, Evotec SE, Taconic Biosciences, The Jackson Laboratory |
Other key industry trends
- In terms of revenue, China accounted for 2.4% of the global oncology based in-vivo cro market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Asia Pacific, Japan oncology based in-vivo cro market is projected to lead the regional market in terms of revenue in 2030.
- China is the fastest growing regional market in Asia Pacific and is projected to reach USD 63.2 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Oncology Based In-vivo CRO Market Scope
Oncology Based In-vivo CRO Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
China oncology based in-vivo cro market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to oncology based in-vivo cro market will help companies and investors design strategic landscapes.
Solid tumor was the largest segment with a revenue share of 47.13% in 2023. Horizon Databook has segmented the China oncology based in-vivo cro market based on blood cancer, solid tumor covering the revenue growth of each sub-segment from 2018 to 2030.
As China is progressively becoming a powerhouse of science & innovation, the pharmaceutical industry is seeing for extensive collaboration with the local Chinese organizations including CROs to build a real presence in the country. Over the past five years, the pharmaceutical industry in China has moved its focus to R&D of novel treatments from generics manufacturing.
As per the annual R&D review of Informa’s Pharmaprojects for 2019, China is the world’s second-biggest producer of drugs. This is largely owing to the increasing number of domestic pharmaceutical firms focusing on drug discovery & development.
Big pharmaceutical firms have followed this trend & stepped up their licensing deals with Chinese companies in 2019 & 2019. The pharmaceutical giants have also opened up new & expanded current research facilities in China. For instance, in November 2019, AstraZeneca created a new international R&D center in Shanghai that doubled its research strength in the city.
Reasons to subscribe to China oncology based in-vivo cro market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of China oncology based in-vivo cro market databook
-
Our clientele includes a mix of oncology based in-vivo cro market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the China oncology based in-vivo cro market , including forecasts for subscribers. This country databook contains high-level insights into China oncology based in-vivo cro market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
China oncology based in-vivo cro market size, by indication, 2018-2030 (US$M)
China Oncology Based In-vivo CRO Market Outlook Share, 2023 & 2030 (US$M)
Related industry reports
Related regional statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
